Edition:
United States

Kura Oncology Inc (KURA.OQ)

KURA.OQ on NASDAQ Stock Exchange Global Select Market

18.94USD
22 Jul 2019
Change (% chg)

-- (--)
Prev Close
$18.94
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
88,127
52-wk High
$22.00
52-wk Low
$10.24

Latest Key Developments (Source: Significant Developments)

Kura Oncology Expands Protection For Tipifarnib With New U.S. & European Patents
Thursday, 11 Jul 2019 07:30am EDT 

July 11 (Reuters) - Kura Oncology Inc ::KURA ONCOLOGY EXPANDS PROTECTION FOR TIPIFARNIB WITH NEW U.S. AND EUROPEAN PATENTS.KURA ONCOLOGY - U.S. PATENT AND TRADEMARK OFFICE ISSUED & EUROPEAN PATENT OFFICE GRANTED NEW PATENTS PROTECTING CO'S LEAD DRUG CANDIDATE, TIPIFARNIB.  Full Article

Kura Oncology Announces Positive Mid-Stage Trial Of Tipifarnib In Peripheral T-Cell Lymphoma
Friday, 14 Jun 2019 07:00am EDT 

June 14 (Reuters) - Kura Oncology Inc ::KURA ONCOLOGY ANNOUNCES POSITIVE PHASE 2 TRIAL OF TIPIFARNIB IN PERIPHERAL T-CELL LYMPHOMA.KURA ONCOLOGY INC - 50% CR RATE AND 75% ORR OBSERVED IN AITL PATIENTS WITH KIR MUTATIONS, A CXCL PATHWAY-ASSOCIATED MARKER.KURA ONCOLOGY INC - BELIEVES RESULTS SUPPORT MULTIPLE REGISTRATIONAL OPPORTUNITIES IN RELAPSED/REFRACTORY LYMPHOMA AND PLANS TO SEEK REGULATORY FEEDBACK.KURA ONCOLOGY INC - PRIMARY ENDPOINT ACHIEVED WITH 45% AND 42% ORR IN AITL AND CXCL12+ AITL/PTCL-NOS EXPANSION COHORTS.KURA ONCOLOGY INC - EVALUATING POTENTIAL TO USE CXCL12 PATHWAY BIOMARKERS TO ENRICH FOR CLINICAL ACTIVITY IN OTHER HEMATOLOGIC MALIGNANCIES.KURA ONCOLOGY INC - TIPIFARNIB WAS GENERALLY WELL-TOLERATED IN PHASE 2 TRIAL, WITH ADVERSE EVENTS CONSISTENT WITH ITS KNOWN SAFETY PROFILE.KURA ONCOLOGY - LYMPHOMA PATIENTS WITH CXCL12 REFERENCE SEQUENCES ALSO APPEARED TO HAVE A HIGHER CHANCE OF CLINICAL BENEFIT FROM TIPIFARNIB TREATMENT.KURA ONCOLOGY INC - IN ADDITION TO AITL, HIGH CXCL12 EXPRESSION WAS OBSERVED IN TUMORS FROM OTHER LYMPHOMA PATIENTS.  Full Article

Kura Oncology Qtrly Net Loss Per Share $0.37
Tuesday, 7 May 2019 04:05pm EDT 

May 7 (Reuters) - Kura Oncology Inc ::KURA ONCOLOGY REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS UPCOMING MILESTONES.KURA ONCOLOGY INC - $165.5 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS PROVIDE RUNWAY INTO 2021.KURA ONCOLOGY INC - QTRLY NET LOSS PER SHARE, $ 0.37.  Full Article

Kura Oncology Files For Mixed Shelf Of Up To $200 Mln
Monday, 5 Nov 2018 04:51pm EST 

Nov 5 (Reuters) - Kura Oncology Inc ::KURA ONCOLOGY INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING.  Full Article

Kura Oncology Q3 Loss Per Share $0.40
Monday, 5 Nov 2018 04:05pm EST 

Nov 5 (Reuters) - Kura Oncology Inc ::KURA ONCOLOGY REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.40.Q3 EARNINGS PER SHARE VIEW $-0.43 -- THOMSON REUTERS I/B/E/S.  Full Article

Kura Oncology Provides Regulatory Update On Tipifarnib
Monday, 12 Mar 2018 04:05pm EDT 

March 12 (Reuters) - Kura Oncology Inc ::KURA ONCOLOGY PROVIDES REGULATORY UPDATE ON TIPIFARNIB AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.KURA ONCOLOGY INC - ‍EXPECTS CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TO BE SUFFICIENT TO FUND CURRENT OPERATIONS INTO FIRST HALF OF 2020​.KURA ONCOLOGY - ‍ TIPIFARNIB HAS BEEN GENERALLY WELL-TOLERATED WITH ADVERSE EVENTS OBSERVED CONSISTENT WITH ITS KNOWN SAFETY PROFILE​ IN PHASE 2 TRIAL.KURA ONCOLOGY INC - PLANS TO ‍INITIATE TIPIFARNIB AIM-HN TRIAL IN HRAS MUTANT HNSCC IN SECOND HALF OF 2018​.KURA ONCOLOGY INC - SUBMISSION OF AN INVESTIGATIONAL NEW DRUG APPLICATION FOR KO-539 IN LATE 2018 OR EARLY 2019.KURA ONCOLOGY INC - QTRLY LOSS PER SHARE $0.37.  Full Article

Kura Oncology files for mixed shelf offering of up to $200 mln - SEC filing‍​
Thursday, 9 Nov 2017 05:28pm EST 

Nov 9 (Reuters) - Kura Oncology Inc :Kura Oncology Inc - files for mixed shelf offering of up to $200 million - SEC filing‍​.  Full Article

Kura Oncology reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Kura Oncology Inc ::Kura Oncology reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.38.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

KURA ONCOLOGY ‍CONFIRMS PARTIAL RESPONSES OBSERVED IN PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL
Friday, 27 Oct 2017 10:50am EDT 

Oct 27 (Reuters) - Kura Oncology Inc :KURA ONCOLOGY LEAD CANDIDATE TIPIFARNIB SHOWS DURABLE ANTI-TUMOR ACTIVITY IN HRAS MUTANT HEAD AND NECK CANCER IN AACR-NCI-EORTC UPDATE.‍CONFIRMED PARTIAL RESPONSES OBSERVED IN FOUR OUT OF SIX PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL​.BASED ON POSITIVE RESULTS FROM PHASE 2 TRIAL, CO PLANS TO INITIATE A REGISTRATION-ENABLING STUDY IN HRAS MUTANT HNSCC IN 2018​.  Full Article

‍Great Point Partners LLC reports 5.92 percent passive stake ​in Kura Oncology Inc
Monday, 21 Aug 2017 04:18pm EDT 

Aug 21 (Reuters) - ‍Great Point Partners LLC::‍Great Point Partners LLC reports 5.92 percent passive stake ​in Kura Oncology Inc <<>> as on August 11, 2017 - sec filing.  Full Article